Figure 8

Impact of ERK1/2 on bradykinin-induced IL-8 release and its augmentation by cAMP analogs. Cells were pretreated for 30 min with 3 μM U0126 or vehicle before the addition of 10 μM bradykinin (15 min), 100 μM 8-pCPT-2-O-Me-cAMP or 500 μM 6-Bnz-cAMP (each 5 min) (A). Phosphorylated ERK1/2 (P-ERK1/2) and total ERK1/2 were detected by specific antibodies. Representative immunoblots are shown on the left with the respective densitometric quantifications on the right (n = 5). Alternatively, cells were treated with bradykinin alone or in combination with 100 μM 8-pCPT-2'-O-Me-cAMP or 500 μM 6-Bnz-cAMP for 18 hrs. Thereafter, IL-8 release was measured by ELISA (B). Results represent mean ± SEM of separate experiments (n = 3-9). *P < 0.05, **P < 0.01, ***P < 0.001 compared to unstimulated control; ^§ P < 0.05, ^§§ P < 0.01, ^§§§ P < 0.001 compared to basal condition.